The Company's adjusted earnings guidance for 2008 excludes the impact of amortization costs associated with acquired products, contributions and/or losses from the DDD&I operations that the Company plans to divest, and incremental depreciation related to purchase accounting. The Company's adjusted earnings guidance also excludes the impact of any unscheduled launches resulting from patent challenges, other business development activities, and refinancing activities that may be completed after the date hereof and on or before December 31, 2008.
The Company will host a Conference Call at 8:30 AM Eastern time on Thursday, May 8, 2008 to discuss earnings results for the quarter ended March 31, 2008. The number to call from within the United States is (800) 553-5275 and (612) 332-0345 Internationally. A replay of the conference call will be available from 10:30 AM Eastern time on May 8, 2008 through 11:59 PM Eastern time May 22, 2008 and can be accessed by dialing (800) 475-6701 in the United States or (320) 365-3844 Internationally and using the access code 918406.
The Conference Call will also be Webcast live on the Internet. Investors and other interested parties may access the live webcast through the Investors section, under Calendar of Events, on Barr's website at http://www.barrlabs.com.
Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.
About Barr Pharmaceuticals, Inc.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company
that operates in more than 30 countries worldwide and is engaged in the
development, manufacture and marketi
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved